Added to YB: 2026-09-18
Pitch date: 2026-09-15
GUTS [neutral]
Fractyl Health, Inc.
Author Info
No bio for this author
Company Info
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
Market Cap
$89.9M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.31
P/E
-0.70
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
special_situation
Biotech Conference Coverage: Week 2, Day 1 — Part 3 - Fractyl Health, Inc.
GUTS (quick overview): Fractyl Health’s lead opportunity is Revita, an endoscopic procedure targeting weight regain after GLP-1 discontinuation. Midpoint data showed 4.5% regain versus 7.5% with sham; the ~300-patient pivotal readout is expected in early Q4 2026. Revita must demonstrate durable clinical value sufficient to overcome procedure and reimbursement burdens, while less than $50 million of Q2 cash and runway into early 2027 make post-data financing or a strategic transaction likely.
Read full article (2 min)